Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford team who have developed a COVID-19 vaccine in record time have been shortlisted for the Excellence in Healthcare Award at the NHS Parliamentary Awards.

Scientists analyzing covid 19 sample with microscope and holding covid 19 blood sample tube

The team from the Oxford Vaccine Group and Jenner Institute were nominated by Layla Moran, MP for Oxford West and Abingdon, and won the regional Excellence in Healthcare award.

The news coincided with announcement of interim data from phase III of the vaccine trial, which showed that the Oxford candidate vaccine was effective at preventing COVID-19 and offered a high level of protection. One dosing regimen indicated that the vaccine is 90 percent effective.

Layla Moran said:

"I'm absolutely delighted. There were nearly 700 nominations by MPs this year, so to be shortlisted is a huge achievement - the vaccine team really deserve it!

"The Oxford Vaccine Group and the Jenner Institute have been working so incredibly hard since the beginning of the pandemic to produce a vaccine that will be life changing for so many people around the world."

The NHS Parliamentary Awards are an annual opportunity to recognise and appreciate the very best about our local healthcare service.

The full story is available on the Oxford University Hospitals website

Similar stories

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.